Trial Profile

A PHASE 1, RANDOMIZED, OPEN LABEL, PARTIAL CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF THREE AGE-APPROPRIATE MODIFIED RELEASE FORMULATIONS AND THE IMMEDIATE RELEASE SOLUTION OF TOFACITINIB IN HEALTHY ADULT VOLUNTEERS

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tofacitinib (Primary) ; Tofacitinib
Indications Ankylosing spondylitis; Atopic dermatitis; Diffuse scleroderma; Juvenile rheumatoid arthritis; Plaque psoriasis; Pneumonia; Psoriatic arthritis; Pulmonary sarcoidosis; Rheumatoid arthritis; Ulcerative colitis
Focus Pharmacokinetics
Sponsors Pfizer

27 Oct 2020 Status changed from recruiting to completed.
29 Jul 2020 Planned End Date changed from 14 Oct 2020 to 15 Sep 2020.
29 Jul 2020 Planned primary completion date changed from 14 Oct 2020 to 15 Sep 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com